Vaccinex(VCNX) - 2023 Q1 - Quarterly Report

Financial Performance - The company reported a net loss of $4.986 million for the three months ended March 31, 2023, compared to a net loss of $4.594 million for the same period in 2022[93]. - For the three months ended March 31, 2023, the company reported a net loss of $5.0 million, consistent with the $4.6 million loss reported for the same period in 2022[104]. - The company has not generated any revenue from product sales to date, leading to significant net losses and negative cash flows from operations[98]. - The company has raised concerns about its ability to continue as a going concern due to recurring net losses and negative cash flows from operations[86]. - The company anticipates continued losses as it develops and seeks regulatory approvals for its product candidates[104]. Revenue and Expenses - Total revenue for the three months ended March 31, 2023, was $550,000, which included $500,000 from a collaboration agreement and $50,000 in service revenue[88][95]. - Research and development expenses increased by $846,000, or 29%, to $3.812 million for the three months ended March 31, 2023, primarily due to increased patient enrollment in clinical trials[96]. - General and administrative expenses rose by $96,000, or 6%, to $1.724 million for the same period[97]. - Cash used in operating activities for the three months ended March 31, 2023, was $5.0 million, the same as in the previous year[109]. Cash Position - Cash and cash equivalents were $3.3 million as of March 31, 2023, down from $6.4 million as of December 31, 2022[85]. - As of March 31, 2023, the company had cash and cash equivalents of $3.3 million, down from $6.4 million as of December 31, 2022[103]. - Financing activities provided $2.0 million during the three months ended March 31, 2023, compared to $13.2 million in the same period of 2022[111]. Capital Raising - The company entered into a stock purchase agreement in March 2023, raising $2.04 million by selling 4,975,608 shares at $0.41 per share[87]. - The company raised $2.04 million from the sale of 4,975,608 shares at $0.41 per share in March 2023, followed by $2.96 million from the sale of 7,908,516 shares at $0.37 per share in May 2023[99]. Product Development - The lead product candidate, pepinemab, is in clinical development for Alzheimer's disease, Huntington's disease, and various cancers, with topline data for the Alzheimer's study expected in mid-2024[94]. - The company is evaluating its development strategy for pepinemab in Huntington's disease and has requested a Type C meeting with the FDA to discuss a potential Phase 3 study[94]. - The company intends to use proceeds from private placements and funding from the Alzheimer's Drug Discovery Foundation for the development of pepinemab and general corporate purposes[105]. Regulatory and Compliance - The company will no longer qualify as an "emerging growth company" after December 31, 2023, losing certain exemptions from public company requirements[113]. - The company has an accumulated deficit of $324.6 million as of March 31, 2023, compared to $319.7 million as of December 31, 2022[104].